PD-1 checkpoint inhibitors such as nivolumab and pembrolizumab, alone or in conjunction with anti-CTLA-4 agents, demonstrated significant efficacy in enhancing the body’s immune response against melanoma cells [3]. This evidence concerns the gene CTLA4 and melanoma.